Literature DB >> 15869464

Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.

Brian Christensen1, Mette S Nielsen, Kim F Haselmann, Torben E Petersen, Esben S Sørensen.   

Abstract

OPN (osteopontin) is an integrin-binding highly phosphorylated glycoprotein, recognized as a key molecule in a multitude of biological processes such as bone mineralization, cancer metastasis, cell-mediated immune response, inflammation and cell survival. A significant regulation of OPN function is mediated through PTM (post-translational modification). Using a combination of Edman degradation and MS analyses, we have characterized the complete phosphorylation and glycosylation pattern of native human OPN. A total of 36 phosphoresidues have been localized in the sequence of OPN. There are 29 phosphorylations (Ser8, Ser10, Ser11, Ser46, Ser47, Thr50, Ser60, Ser62, Ser65, Ser83, Ser86, Ser89, Ser92, Ser104, Ser110, Ser113, Thr169, Ser179, Ser208, Ser218, Ser238, Ser247, Ser254, Ser259, Ser264, Ser275, Ser287, Ser292 and Ser294) located in the target sequence of MGCK (mammary gland casein kinase) also known as the Golgi kinase (S/T-X-E/S(P)/D). Six phosphorylations (Ser101, Ser107, Ser175, Ser199, Ser212 and Ser251) are located in the target sequence of CKII (casein kinase II) [S-X-X-E/S(P)/D] and a single phosphorylation, Ser203, is not positioned in the motif of either MGCK or CKII. The 36 phosphoresidues represent the maximal degree of modification since variability at many sites was seen. Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN. The phosphorylations are arranged in clusters of three to five phosphoresidues and the regions containing the glycosylations and the RGD (Arg-Gly-Asp) integrin-binding sequence are devoid of phosphorylations. Knowledge about the positions and nature of PTMs in OPN will allow a rational experimental design of functional studies aimed at understanding the structural and functional interdependences in diverse biological processes in which OPN is a key molecule.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15869464      PMCID: PMC1184582          DOI: 10.1042/BJ20050341

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation.

Authors:  Georg F Weber; Samer Zawaideh; Sherry Hikita; Vikram A Kumar; Harvey Cantor; Samy Ashkar
Journal:  J Leukoc Biol       Date:  2002-10       Impact factor: 4.962

Review 2.  One-thousand-and-one substrates of protein kinase CK2?

Authors:  Flavio Meggio; Lorenzo A Pinna
Journal:  FASEB J       Date:  2003-03       Impact factor: 5.191

3.  Osteopontin posttranslational modifications, possibly phosphorylation, are required for in vitro bone resorption but not osteoclast adhesion.

Authors:  S Razzouk; J C Brunn; C Qin; C E Tye; H A Goldberg; W T Butler
Journal:  Bone       Date:  2002-01       Impact factor: 4.398

4.  Identification and characterization of the carboxyl-terminal region of rat dentin sialoprotein.

Authors:  C Qin; R G Cook; R S Orkiszewski; W T Butler
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

5.  Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals.

Authors:  J R Hoyer; J R Asplin; L Otvos
Journal:  Kidney Int       Date:  2001-07       Impact factor: 10.612

6.  Natural variation in the extent of phosphorylation of bone phosphoproteins as a function of in vivo new bone formation induced by demineralized bone matrix in soft tissue and bony environments.

Authors:  Erdjan Salih; Jinxi Wang; James Mah; Rudolf Fluckiger
Journal:  Biochem J       Date:  2002-06-01       Impact factor: 3.857

7.  Phosphopeptide analysis by matrix-assisted laser desorption time-of-flight mass spectrometry.

Authors:  R S Annan; S A Carr
Journal:  Anal Chem       Date:  1996-10-01       Impact factor: 6.986

8.  Purification and characterization of osteopontin from human milk.

Authors:  Steen Sørensen; Steen Just Justesen; Anders H Johnsen
Journal:  Protein Expr Purif       Date:  2003-08       Impact factor: 1.650

9.  Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone.

Authors:  A L Boskey; L Spevak; E Paschalis; S B Doty; M D McKee
Journal:  Calcif Tissue Int       Date:  2002-06-20       Impact factor: 4.333

10.  Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.

Authors:  Gabriele Carlinfante; Daphne Vassiliou; Olle Svensson; Mikael Wendel; Dick Heinegård; Göran Andersson
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more
  75 in total

1.  The effect of intracrystalline and surface-bound osteopontin on the degradation and dissolution of calcium oxalate dihydrate crystals in MDCKII cells.

Authors:  Lauren A Thurgood; Esben S Sørensen; Rosemary L Ryall
Journal:  Urol Res       Date:  2011-09-20

2.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

3.  PRISMOID: a comprehensive 3D structure database for post-translational modifications and mutations with functional impact.

Authors:  Fuyi Li; Cunshuo Fan; Tatiana T Marquez-Lago; André Leier; Jerico Revote; Cangzhi Jia; Yan Zhu; A Ian Smith; Geoffrey I Webb; Quanzhong Liu; Leyi Wei; Jian Li; Jiangning Song
Journal:  Brief Bioinform       Date:  2020-05-21       Impact factor: 11.622

Review 4.  Extracellular Protein Phosphorylation, the Neglected Side of the Modification.

Authors:  Eva Klement; Katalin F Medzihradszky
Journal:  Mol Cell Proteomics       Date:  2016-11-10       Impact factor: 5.911

5.  Isoform-specific O-glycosylation of osteopontin and bone sialoprotein by polypeptide N-acetylgalactosaminyltransferase-1.

Authors:  Hazuki E Miwa; Thomas A Gerken; Oliver Jamison; Lawrence A Tabak
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

6.  Large-scale proteomics and phosphoproteomics of urinary exosomes.

Authors:  Patricia A Gonzales; Trairak Pisitkun; Jason D Hoffert; Dmitry Tchapyjnikov; Robert A Star; Robert Kleta; Nam Sun Wang; Mark A Knepper
Journal:  J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 10.121

7.  The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways.

Authors:  Donald Courter; Hongbin Cao; Shirley Kwok; Christina Kong; Alice Banh; Peiwen Kuo; Donna M Bouley; Carmen Vice; Odd Terje Brustugun; Nicholas C Denko; Albert C Koong; Amato Giaccia; Quynh-Thu Le
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

8.  Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.

Authors:  Antje Hahnel; Henri Wichmann; Matthias Kappler; Matthias Kotzsch; Dirk Vordermark; Helge Taubert; Matthias Bache
Journal:  Radiat Oncol       Date:  2010-09-17       Impact factor: 3.481

9.  Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D.

Authors:  Brian Christensen; Lotte Schack; Eva Kläning; Esben S Sørensen
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

10.  The role of osteopontin in inflammatory processes.

Authors:  Susan Amanda Lund; Cecilia M Giachelli; Marta Scatena
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.